CN107982318A - 一种降血糖的中药复方组合物 - Google Patents
一种降血糖的中药复方组合物 Download PDFInfo
- Publication number
- CN107982318A CN107982318A CN201711331121.4A CN201711331121A CN107982318A CN 107982318 A CN107982318 A CN 107982318A CN 201711331121 A CN201711331121 A CN 201711331121A CN 107982318 A CN107982318 A CN 107982318A
- Authority
- CN
- China
- Prior art keywords
- medicine
- chinese medicine
- traditional chinese
- martynoside
- cassia tree
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 46
- 210000004369 blood Anatomy 0.000 title claims abstract description 29
- 239000008280 blood Substances 0.000 title claims abstract description 29
- 150000001875 compounds Chemical class 0.000 title claims abstract description 27
- 230000003247 decreasing effect Effects 0.000 title claims abstract description 13
- 241000522254 Cassia Species 0.000 claims abstract description 21
- VDWSYBFEQXWINA-UHFFFAOYSA-N Martinoside Natural products C1=C(O)C(OC)=CC=C1CCOC1C(O)C(OC2C(C(O)C(O)C(C)O2)O)C(OC(=O)C=CC=2C=C(O)C(OC)=CC=2)C(CO)O1 VDWSYBFEQXWINA-UHFFFAOYSA-N 0.000 claims abstract description 19
- WLWAYPFRKDSFCL-CNMJWYMJSA-N [(2r,3r,4r,5r,6r)-5-hydroxy-6-[2-(3-hydroxy-4-methoxyphenyl)ethoxy]-2-(hydroxymethyl)-4-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate Chemical compound C1=C(O)C(OC)=CC=C1CCO[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@H](OC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)[C@@H](CO)O1 WLWAYPFRKDSFCL-CNMJWYMJSA-N 0.000 claims abstract description 19
- RLGRBYHBNWLGER-UHFFFAOYSA-N cistanoside D Natural products C1=C(O)C(OC)=CC(CCOC2C(C(OC3C(C(O)C(O)C(C)O3)O)C(OC(=O)C=CC=3C=C(OC)C(O)=CC=3)C(CO)O2)O)=C1 RLGRBYHBNWLGER-UHFFFAOYSA-N 0.000 claims abstract description 19
- ZMYQRHSOVRDQDL-NSWBACJASA-N leucosceptoside A Natural products COc1cc(C=CC(=O)O[C@@H]2[C@@H](CO)O[C@@H](OCCc3ccc(O)c(O)c3)[C@H](O)[C@H]2O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)ccc1O ZMYQRHSOVRDQDL-NSWBACJASA-N 0.000 claims abstract description 19
- WLWAYPFRKDSFCL-AYPSUWEUSA-N martynoside Natural products COc1ccc(CCO[C@@H]2O[C@H](CO)[C@@H](OC(=O)C=Cc3ccc(O)c(OC)c3)[C@H](O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@H]2O)cc1O WLWAYPFRKDSFCL-AYPSUWEUSA-N 0.000 claims abstract description 19
- 241000405414 Rehmannia Species 0.000 claims abstract description 15
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 150000004676 glycans Chemical class 0.000 claims abstract description 12
- 239000005017 polysaccharide Substances 0.000 claims abstract description 12
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 12
- 229930003944 flavone Natural products 0.000 claims abstract description 11
- 235000011949 flavones Nutrition 0.000 claims abstract description 11
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 10
- 229930185474 acteoside Natural products 0.000 claims abstract description 10
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 claims abstract description 10
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 claims abstract description 10
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 claims abstract description 10
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- FBSKJMQYURKNSU-ZLSOWSIRSA-N acteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FBSKJMQYURKNSU-ZLSOWSIRSA-N 0.000 claims abstract description 9
- FBSKJMQYURKNSU-UKQWSTALSA-N acteoside I Natural products C[C@@H]1O[C@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O FBSKJMQYURKNSU-UKQWSTALSA-N 0.000 claims abstract description 9
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 9
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 9
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 9
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000470 constituent Substances 0.000 claims abstract description 4
- 230000036541 health Effects 0.000 claims abstract description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229930182478 glucoside Natural products 0.000 claims description 2
- 150000008131 glucosides Chemical class 0.000 claims 1
- 239000008103 glucose Substances 0.000 abstract description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 7
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 5
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 4
- 230000003914 insulin secretion Effects 0.000 abstract description 4
- 208000002249 Diabetes Complications Diseases 0.000 abstract description 3
- 206010012655 Diabetic complications Diseases 0.000 abstract description 3
- 230000003908 liver function Effects 0.000 abstract description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 13
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- -1 flavone compounds Chemical class 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 206010023379 Ketoacidosis Diseases 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 241000336316 Cistanche tubulosa Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- UBORTCNDUKBEOP-UHFFFAOYSA-N L-xanthosine Natural products OC1C(O)C(CO)OC1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UHFFFAOYSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- UBORTCNDUKBEOP-HAVMAKPUSA-N Xanthosine Natural products O[C@@H]1[C@H](O)[C@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-HAVMAKPUSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 208000037890 multiple organ injury Diseases 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- UBORTCNDUKBEOP-UUOKFMHZSA-N xanthosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UUOKFMHZSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及天然药物领域，尤其涉及一种降血糖的中药复方组合物，所述中药复方组合物包括以下重量数的药物活性成分：肉桂总黄酮5‑10mg/g、肉桂多酚6‑11mg/g、原花青素0.5‑1.0 mg/g、熟地黄多糖10‑16mg/g、地黄苷A 0.6‑1.5mg/g、地黄苷D 0.6‑1.6mg/g、毛蕊花糖苷0.5‑1.5mg/g和梓醇0.4‑7.2mg/g，本发明中的降血糖中药组合物产品稳定，具有增加胰岛素敏感性、促进胰岛素分泌、降低血糖的作用，同时具有调节血脂、改善肝功能的作用；本发明的组合物在治疗和预防糖尿病、糖尿病并发症和调节血脂药品或保健品中有广泛的应用。
Description
技术领域
本发明涉及天然药物领域，尤其涉及一种降血糖的中药复方组合物。
背景技术
糖尿病是一种常见、多发的内分泌代谢紊乱疾病，具体病因和发病机制不明，一般认为是由于体内胰岛素缺乏或其不能正常发挥生理作用引起糖代谢紊乱，继而导致蛋白质、脂肪、水、电解质等多种物质代谢紊乱的一种综合病症，属于传统中医“消渴病”范畴。糖尿病，临床以高血糖为主要标志，主要分为1型 (胰岛素依赖型，IDDM)和2 型 (非胰岛素依赖型，NIDDM) 两种，前者乃因胰岛素绝对缺乏，胰岛β细胞分泌极少胰岛素，以至于不能抑制脂肪分解，有大量酮体产生而导致酮症酸中毒 (DKA)，1型糖尿病患者主要是依赖胰岛素治疗。2型糖尿病患者的胰岛 β 细胞仍有一定量胰岛素分泌功能，足以抑制脂肪组织过多游离脂肪酸释放，防止自发性酮症酸中毒的发生，但高血糖长时期存在。2型糖尿病患者的病症主要表现为代谢异常，最为典型的就是胰岛素抵抗和胰岛素缺乏，这些异常导致血糖升高，进而提升了发生心血管方面疾病的可能。针对 2 型糖尿病，目前常用口服降糖药以促胰岛素分泌剂和胰岛素增敏剂为主。用于2型糖尿病的治疗，还有一种α-葡萄糖苷酶抑制剂，这类药物能提高肌肉、脂肪对葡萄糖的摄取和利用、抑制肝脏葡萄糖的输出、降低血糖。但是2型糖尿病为一种慢性疾病，需终生服药，在控制血糖的同时，西药不良反应随之出现。长期服药会给患者带来诸多器官损伤，有些反应较严重甚至引起死亡。其中不良反应包括低血糖、心血管副反应、消化道副反应、乳酸性酸中毒以及肝肾毒性等。因此糖尿病患者急切地需要使用方便、作用高效、稳定、持久、毒性和副作用较小并可以延缓并发症发生发展的降血糖新药。
发明内容
本发明要解决的技术问题是提供一种降血糖的中药复方组合物，用于治疗和预防糖尿病、糖尿病并发症。
一种降血糖的中药复方组合物，所述中药复方组合物包括以下重量数的药物活性成分：肉桂总黄酮5-10mg/g、肉桂多酚6-11mg/g、原花青素0.5-1.0 mg/g、熟地黄多糖10-16mg/g、地黄苷A 0.6-1.5mg/g、地黄苷D 0.6-1.6mg/g、毛蕊花糖苷0.5-1.5mg/g和梓醇0.4-7.2mg/g。
进一步的，所述中药复方组合物包括以下重量数的药物活性成分：肉桂总黄酮6-8mg/g、肉桂多酚8-10mg/g、原花青素0.6-0.8 mg/g、熟地黄多糖12-14mg/g、地黄苷A 0.8-1.0mg/g、地黄苷D 0.8-1.2mg/g、毛蕊花糖苷0.8-1.1mg/g和梓醇3.0-5.0mg/g。
进一步的，所述中药复方组合物还含有药学上可接受的载体。
进一步的，所述中药复方组合物用于制备治疗或预防糖尿病或高脂血症的药食两用保健品或药品的用途。
肉桂总黄酮：肉桂又名玉桂和桂皮，是一种珍贵的药、食及日用化工产品的香料药材，肉桂的成分比较复杂，含有挥发性成分、多糖类、萜类、酚类、黄酮类化合物等物质，其中抗氧化成分种类值得关注， 肉桂挥发油抗氧化性取得一定进展，大量研究结果表明，黄酮类化合物具有治疗心脑血管疾病、抗菌、消炎、镇痛、抗病毒、抗肿瘤、降低血糖、降血脂等作用；
肉桂多酚：酚类是肉桂中的一种重要成分，可以增加胰岛素敏感性，从而降低代谢综合症，糖尿病的危险；
原花青素：是植物中广泛存在的一大类多酚化合物的总称，具有极强的抗氧化、消除自由基的作用，可有效消除超氧阴离子自由基和羟基自由基，也参与磷酸、花生四烯酸的代谢和蛋白质磷酸化，保护脂质不发生过氧化损伤，是强有力的金属螯合剂，可螯合金属离子，在体内形成惰性化合物；保护和稳定维生素C，有助于维生素C的吸收和利用，原花青素还可以清除细胞膜中水溶性和脂溶性的自由基，因此，抑制了释放某些酶去伤害毛细血管壁的过程；
熟地黄多糖：熟地黄多糖是“药食同源”熟地黄中特有的活性成分之一，药理研究表明，熟地黄多糖有增强免疫、抗肿瘤、补血等生理功能。
地黄苷A：地黄为玄参科植物地黄的干燥块茎，具清热凉血、养阴、生津之功效，地黄苷A具有滋阴和调节免疫的作用，能够增强体液免疫和细胞免疫功能；
地黄苷D：地黄具有调节免疫功能， 抗肿瘤、抗衰老、降血糖的作用， 对心血管系统、造血系统、内分泌系统、中枢神经系统等均表现出一定的药理活性，地黄苷D是地黄中的主要有效成分之一；
毛蕊花糖苷：毛蕊花糖苷在灌胃20天后可以降低糖尿病小鼠的空腹血糖；灌胃45天后可以降低小鼠的空腹血糖、餐后血糖和血脂，提高血清胰岛素水平，并可提高肌糖原含量、增强胰岛素降血糖的效果.提示毛蕊花糖苷是管花肉苁蓉中起控糖功效的主要活性成分，其作用机制之一是通过抑制肠道α-葡萄糖苷酶从而降低碳水化合物在肠道内的消化吸收；
梓醇：梓醇有抗癌、神经保护、抗炎、利尿、降血糖及抗肝炎病毒等作用，它是一种环烯醚萜葡萄糖苷类化合物，主要存在于地黄等植物中。
与现有技术相比，本发明具有如下技术优势：
本发明中的降血糖中药组合物产品稳定，具有增加胰岛素敏感性、促进胰岛素分泌、降低血糖的作用，同时具有调节血脂、改善肝功能的作用；本发明的组合物在治疗和预防糖尿病、糖尿病并发症和调节血脂药品或保健品中有广泛的应用。
具体实施方式
本领域技术人员应理解，以下实施例中所公开的技术代表本发明人发现的在本发明的实践中发挥良好作用的技术。然而，在所公开的具体实施方案中可以做出许多改变，并仍然获得相同或相似的结果，而不脱离本发明的精神和范围。
实施例1：
一种降血糖的中药复方组合物，所述中药复方组合物包括以下重量数的药物活性成分：肉桂总黄酮5mg/g、肉桂多酚6mg/g、原花青素0.5 mg/g、熟地黄多糖10mg/g、地黄苷A0.6mg/g、地黄苷D 0.6mg/g、毛蕊花糖苷0.5mg/g和梓醇0.4mg/g。
实施例2：
一种降血糖的中药复方组合物，所述中药复方组合物包括以下重量数的药物活性成分：肉桂总黄酮10mg/g、肉桂多酚11mg/g、原花青素1.0 mg/g、熟地黄多糖16mg/g、地黄苷A1.5mg/g、地黄苷D1.6mg/g、毛蕊花糖苷1.5mg/g和梓醇7.2mg/g。
实施例3：
一种降血糖的中药复方组合物，所述中药复方组合物包括以下重量数的药物活性成分：肉桂总黄酮8mg/g、肉桂多酚8mg/g、原花青素0.8 mg/g、熟地黄多糖13mg/g、地黄苷A1.0mg/g、地黄苷D 1.1mg/g、毛蕊花糖苷1.0mg/g和梓醇4.0mg/g。
由于已经通过以上较佳实施例描述了本发明，在本发明的精神和/或范围内，任何针对本发明的替换/或组合来实施本发明，对于本领域的技术人员来说都是显而易见的，且包含在本发明之中。
Claims (4)
1.一种降血糖的中药复方组合物，其特征在于，所述中药复方组合物包括以下重量数的药物活性成分：肉桂总黄酮5-10mg/g、肉桂多酚6-11mg/g、原花青素0.5-1.0 mg/g、熟地黄多糖10-16mg/g、地黄苷A 0.6-1.5mg/g、地黄苷D 0.6-1.6mg/g、毛蕊花糖苷0.5-1.5mg/g和梓醇0.4-7.2mg/g。
2.根据权利要求1所述一种降血糖的中药复方组合物，其特征在于，所述中药复方组合物包括以下重量数的药物活性成分：肉桂总黄酮6-8mg/g、肉桂多酚8-10mg/g、原花青素0.6-0.8 mg/g、熟地黄多糖12-14mg/g、地黄苷A 0.8-1.0mg/g、地黄苷D 0.8-1.2mg/g、毛蕊花糖苷0.8-1.1mg/g和梓醇3.0-5.0mg/g。
3.根据权利要求1所述一种降血糖的中药复方组合物，其特征在于，所述中药复方组合物还含有药学上可接受的载体。
4.根据权利要求1所述一种降血糖的中药复方组合物，其特征在于，所述中药复方组合物用于制备治疗或预防糖尿病或高脂血症的药食两用保健品或药品的用途。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711331121.4A CN107982318A (zh) | 2017-12-13 | 2017-12-13 | 一种降血糖的中药复方组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711331121.4A CN107982318A (zh) | 2017-12-13 | 2017-12-13 | 一种降血糖的中药复方组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107982318A true CN107982318A (zh) | 2018-05-04 |
Family
ID=62038352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711331121.4A Pending CN107982318A (zh) | 2017-12-13 | 2017-12-13 | 一种降血糖的中药复方组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107982318A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108853130A (zh) * | 2018-09-30 | 2018-11-23 | 北京济全生物科技有限公司 | 一种包含梓醇的降血糖药物组合物及其制备方法和用途 |
| CN109010299A (zh) * | 2018-09-30 | 2018-12-18 | 北京济全生物科技有限公司 | 一种缓释降血糖药物组合物及其制备方法和用途 |
| CN109771633A (zh) * | 2019-03-15 | 2019-05-21 | 湖南补天药业股份有限公司 | 一种具有降血糖功能的膏滋及其制备方法 |
| CN112076199A (zh) * | 2019-06-13 | 2020-12-15 | 谢亚坚 | 一种降血糖降血脂和降血胆固醇方剂 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100998650A (zh) * | 2006-12-05 | 2007-07-18 | 高秀丽 | 肉桂在治疗糖尿病上的用途及产品和其制备方法 |
| CN101167802A (zh) * | 2006-10-25 | 2008-04-30 | 中国科学院上海生命科学研究院 | 肉桂提取物的制备方法、肉桂提取物、其组合物以及用途 |
| WO2009018648A1 (en) * | 2007-08-07 | 2009-02-12 | Innovative Life Sciences Corporation | Herbal product comprising cinnamon and coffee for treating diabetes and reducing the risk of cardiovascular disease |
| CN102266388A (zh) * | 2011-07-20 | 2011-12-07 | 天津市聚星康华医药科技有限公司 | 一种用于2型糖尿病及并发症预防和治疗的药物组合物 |
| CN103054895A (zh) * | 2013-01-16 | 2013-04-24 | 济南康众医药科技开发有限公司 | 一种预防和治疗肥胖的药物组合物 |
-
2017
- 2017-12-13 CN CN201711331121.4A patent/CN107982318A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101167802A (zh) * | 2006-10-25 | 2008-04-30 | 中国科学院上海生命科学研究院 | 肉桂提取物的制备方法、肉桂提取物、其组合物以及用途 |
| CN100998650A (zh) * | 2006-12-05 | 2007-07-18 | 高秀丽 | 肉桂在治疗糖尿病上的用途及产品和其制备方法 |
| WO2009018648A1 (en) * | 2007-08-07 | 2009-02-12 | Innovative Life Sciences Corporation | Herbal product comprising cinnamon and coffee for treating diabetes and reducing the risk of cardiovascular disease |
| CN102266388A (zh) * | 2011-07-20 | 2011-12-07 | 天津市聚星康华医药科技有限公司 | 一种用于2型糖尿病及并发症预防和治疗的药物组合物 |
| CN103054895A (zh) * | 2013-01-16 | 2013-04-24 | 济南康众医药科技开发有限公司 | 一种预防和治疗肥胖的药物组合物 |
Non-Patent Citations (2)
| Title |
|---|
| 卢春连 等: "肉桂降糖活性成分提取方法的研究", 《应用化工》 * |
| 李红伟 等: "地黄化学成分及其药理作用研究进展", 《药物评价研究》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108853130A (zh) * | 2018-09-30 | 2018-11-23 | 北京济全生物科技有限公司 | 一种包含梓醇的降血糖药物组合物及其制备方法和用途 |
| CN109010299A (zh) * | 2018-09-30 | 2018-12-18 | 北京济全生物科技有限公司 | 一种缓释降血糖药物组合物及其制备方法和用途 |
| CN108853130B (zh) * | 2018-09-30 | 2019-08-13 | 北京济全生物科技有限公司 | 一种降血糖药物组合物及其制备方法 |
| CN109771633A (zh) * | 2019-03-15 | 2019-05-21 | 湖南补天药业股份有限公司 | 一种具有降血糖功能的膏滋及其制备方法 |
| CN112076199A (zh) * | 2019-06-13 | 2020-12-15 | 谢亚坚 | 一种降血糖降血脂和降血胆固醇方剂 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Baliga et al. | Phytochemistry and medicinal uses of the bael fruit (Aegle marmelos Correa): A concise review | |
| US6291533B1 (en) | Dietary supplements for each specific blood type | |
| CN107982318A (zh) | 一种降血糖的中药复方组合物 | |
| CN108042643A (zh) | 一种降血糖中药复方组合物的制备方法 | |
| CN1143681C (zh) | 治疗糖尿病的药用组合物 | |
| Shane-McWhorter | Dietary supplements for diabetes: an evaluation of commonly used products | |
| CN104940241B (zh) | 一种防治妇女更年期综合征的硒虫草复方制剂 | |
| El-Tantawy | Nutrition in the management of type 2 diabetes mellitus | |
| Hussain et al. | Comparative in vitro analysis of anti-diabetic activity of Indo-Pak black cardamom (Amomum subulatum Roxb.) and Chinese black cardamom (Amomum tsao-ko Crevost et Lemaire) | |
| Tan et al. | A review on the hypoglycemic properties of selected non-leafy vegetables in Malaysia | |
| Winifred et al. | Biochemical studies of the ameliorating effects of bitter leaf and scent leaf extracts on diabetes mellitus in humans | |
| CN102091146A (zh) | 一种含有银杏提取物或单体的组合物 | |
| KR101391647B1 (ko) | 항비만 조성물 | |
| KR20040003888A (ko) | 혈당 강하용 생약 조성물, 이의 제조방법 및 이를포함하는 약학제재 | |
| CN102281882A (zh) | 餐后高血糖改善剂 | |
| Elnour et al. | Effect of Raphanus sativus on Glucose, Cholesterol and Triglycerides Levels in Glucose Loaded Rats | |
| KR20100089910A (ko) | 혼합 생약 추출물을 유효성분으로 함유하는 고지혈증 및 당뇨성 고지혈증의 예방 및 치료용 조성물 | |
| EP2155220B1 (en) | Compositions comprising Herba Ephedrae and Thallus Laminariae seu Eckloniae for use in supressing obesity | |
| Alam et al. | Acid-base and electrolyte balance regulations with phytonutrients | |
| Camilleri et al. | A comprehensive review of the phytochemicals, health benefits, pharmacological safety and medicinal prospects of Moringa oleifera | |
| CN106942439A (zh) | 一种青钱柳番石榴叶降糖茶及其制备方法和用途 | |
| CN102934808B (zh) | 用于解酒的松花粉水提取物口含片 | |
| Ekizce et al. | The pharmacological effects of bitter melon | |
| CN114306373B (zh) | 含白簕中性多糖atp1-1的降脂组合物及其制备方法 | |
| Elbossaty | Hypoglycemic Influence of Phytochemical Compounds of Medicinal Plants and their Mechanism Action |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180504 |